A 48-year-old woman from Mumbai undergoes core needle biopsy for a 3 cm left breast mass. Histopathology confirms invasive ductal carcinoma (IDC), grade 2, with ER/PR positive (80% and 60% respectively) and HER2 negative. Staging CT shows no distant metastases. Physical examination reveals no palpable axillary nodes. What is the most appropriate next step in management?

Explanation

## Clinical Context Confirmed IDC, grade 2, hormone receptor–positive, HER2-negative, M0 disease. Axillary nodal status is unknown clinically. The next step is surgical management with appropriate axillary assessment. ## Why Sentinel Lymph Node Biopsy (SLNB) + BCS is Correct **Key Point:** In early-stage breast cancer (T1–T2, clinically node-negative), sentinel lymph node biopsy is the standard of care for axillary staging, replacing elective axillary dissection. **High-Yield:** Sentinel lymph node biopsy: - Identifies the first lymph node(s) to which cancer drains - Staging accuracy >95% when performed by experienced surgeon - Reduces arm morbidity (lymphedema, seroma) compared to full axillary dissection - Guides adjuvant therapy decisions based on nodal status **Clinical Pearl:** Breast-conserving surgery (BCS) is appropriate for this patient because: - Tumor size 3 cm is borderline but acceptable for BCS if adequate margins achieved - No clinical evidence of multicentric disease - ER/PR positive allows endocrine therapy - BCS + radiation offers equivalent oncologic outcomes to mastectomy in early-stage disease ## Treatment Algorithm for Early-Stage Breast Cancer ```mermaid flowchart TD A[IDC, grade 2, ER/PR+, HER2-, M0]:::outcome --> B[Clinically node-negative?]:::decision B -->|Yes| C[Sentinel lymph node biopsy]:::action C --> D[SLNB result?]:::decision D -->|Negative| E[Breast-conserving surgery + RT]:::action D -->|Positive| F[Axillary dissection + mastectomy consideration]:::action E --> G[Adjuvant endocrine therapy ± chemotherapy]:::action F --> G ``` ## Why Other Options Are Suboptimal | Option | Problem | |--------|----------| | **Mastectomy without SLNB** | Omits axillary staging; cannot determine need for chemotherapy; overtreatment if node-negative | | **Neoadjuvant chemotherapy** | Not indicated for ER/PR+ HER2- tumors without nodal involvement; reserved for locally advanced or HER2+ disease | | **Tamoxifen alone** | Incomplete treatment; omits surgery (local control) and radiation; endocrine therapy is adjuvant, not primary | **Mnemonic:** **SLNB-BCS** = Sentinel Lymph Node Biopsy + Breast-Conserving Surgery for early-stage, clinically node-negative disease. [cite:Robbins 10e Ch 24]